Adjuvant pembrolizumab continue to demonstrate significant improvements for patients with stage IIB/IIC melanoma

For patients with stage IIB/IIC melanoma, adjuvant pembrolizumab provides a 41% reduction in the risk of distant metastasis or death and a 38% reduction in the risk of recurrence or death, according to an update from the KEYNOTE-716 trial presented at ASCO23.